HIVAX is under clinical development by GeneCure Biotechnologies and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect HIVAX’s likelihood of approval (LoA) and phase transition for Human Immunodeficiency Virus (HIV) Infections (AIDS) took place on 26 Sep 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their HIVAX Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

HIVAX overview

HIVAX (replication-defective HIV-1 vaccine) is under development for the treatment of HIV-1 infections. The drug candidate is administered through subcutaneous route. It is developed based on lentiviral-based gene transfer technology.

GeneCure Biotechnologies overview

GeneCure Biotechnologies (GeneCure), formerly GeneCure is a biotechnology company that focuses on the development of gene based technology to treat genetic and acquired human diseases. The company offers products such as Hivax and SimVec. Its Hivax is a patented replication-defective HIV-1 vaccine which stimulates cellular and antibody immune responses in mouse and primate models. GeneCure also develops patented gene transfer technology SimVec based on a primate lentivirus which delivers genes into primary human cells without causing harm to humans. The company also uses its novel gene transfer technology to develop treatments for life-threatening human diseases including genetic diseases, infectious diseases, and cancers. It provides contract manufacturing services. GeneCure is headquartered in Norcross, Georgia, the US.

Quick View HIVAX LOA Data

Report Segments
  • Innovator
Drug Name
  • HIVAX
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Infectious Disease
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.